Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
November 29, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
November 23, 2022 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:05 ET
|
Eyenovia, Inc.
Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device...
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
November 03, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia to Present at the American Academy of Optometry’s Annual Meeting
October 21, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
October 20, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
September 30, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with...
Eyenovia to Present at Upcoming Healthcare Conferences
September 07, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose...
Eyenovia to Participate in Multiple Medical Meetings in September
September 06, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Reports Second Quarter 2022 Financial Results
August 10, 2022 16:05 ET
|
Eyenovia, Inc.
Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi™ NDA resubmission on track for the fourth quarter of 2022 Phase 3 VISION-2 study evaluating...